Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07639554
Starting soon Not applicable

Optimizing Participation In Colorectal Cancer Screening By Direct Invitation Of Non Responders By General Practitionners

NCT07639554 · tracked via the Priya Life Science France tracker
Sponsor
MSPU des 3 Provinces
Phase
Not applicable
Started
2026-12-01
Last updated
2026-09-29

Condition(s) studied

Colorectal Cancer Screening

Investigational drug(s) / intervention(s)

Intervention

Intervention: A telephone call will be made by a member of the patient's primary care team (general practitioner, medical secretary, public health nurse, or care coordinator), with priority given to a call by the patient's general practitioner. The call should preferably be made to the patient's mobile phone. If the call is unsuccessful, a voicemail message will be left, and a second call will be attempted within the following seven days. The voicemail message will include the name of the patient's general practitioner, the purpose of the call regarding colorectal cancer screening, and notification that a further attempt will be made to reach the patient. If the telephone exchange is successful, an appointment at the healthcare facility will be offered to the patient, during which the screening test will be handed over and explained by one of the healthcare professionals from the same facility.

Study summary

The goal of this randomized trial is to assess the effectiveness of a targeted telephone reminder strategy, implemented by the patient's general practitioner, in enhancing participation in colorectal cancer screening among individuals who are not up to date. The participants are patients between 50 and 74 years old, as they are the target population for colorectal cancer screening. The main questions are:

* What is the percentage of patients who completed the colorectal cancer screening test during the intervention year, within the patient population of general practitioners participating in the study and identified as not up to date with their screening?
* Identifying potential factors influencing the effectiveness of the intervention, based on various characteristics of the patient, the geographical area, the general practitioner, and the caller.

Researchers will compare these patients with other patients who are not up to date and did not receive the telephone reminder intervention from their general practitioner.

Eligibility

Sex
ALL
Min age
50 Years
Max age
74 Years
Healthy volunteers
Accepted
Inclusion Criteria for general practitioners: * Practice in one of the four departments of the Franche-Comté region; * Practice in a solo practice, group practice, multidisciplinary primary care centre, or community health centre; * Are engaged in general medical practice; * Have agreed to participate in the study. Inclusion Criteria for patients: * Patients within the practice population of general practitioners selected to participate in the study; * Aged between 50 and 75 years inclusive; * Affiliated with the French general health insurance scheme or the agricultural social insurance scheme. Exclusion Criteria for general practitioners: \- Practice exclusively in a specialty other than general practice (e.g., osteopathy, allergology, vascular medicine). Non-inclusion Criteria for patients: \- Objection expressed by the patient to the change in the purpose of data processing for research purposes.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
MSPU des 3 provinces Champlitte Franche-comté

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07639554 on ClinicalTrials.gov ↗ ← All trials in France